Support for HCM
Committed to people and their families living with Hypertrophic Cardiomyopathy
What is HCM?
HCM is the most commonly inherited form of heart disease that is chronic and progressive in nature. People with HCM may have a higher risk of heart failure, stroke, and atrial fibrillation. Commonly experienced symptoms include breathlessness, irregular heartbeats, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood. This is known as “diastolic dysfunction.”
If you or a loved one have been diagnosed with cardiovascular disease and are experiencing any of the symptoms described above, talk to your doctor about genetic testing for HCM.
Medicines are available for HCM, but people taking may experience limited efficacy, undesirable safety concerns, inconvenient dosing, side effects, and the need for frequent monitoring. While progress has been made for the HCM community, new therapeutic approaches are needed.
Resources
Hypertrophic Cardiomyopathy Association (HCMA)
The preeminent organization improving the lives of those with hypertrophic cardiomyopathy preventing untimely deaths and advancing global understanding.
Edgewise Clinical Trials in HCM
About CIRRUS-HCM, the Phase 2 clinical trial for HCM
We are recruiting a Phase 2 trial of EDG-7500 in HCM patients. There are advantages and disadvantages to participating in a clinical trial. Talk to your doctor or explore the links below to learn more about whether CIRRUS-HCM is right for you.
WHAT IS EDG-7500?
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, intended to slow the excessive rate of early contraction and improve impaired cardiac relaxation associated with obstructive and non-obstructive HCM, and with other diseases of diastolic dysfunction. EDG-7500 is currently in clinical trials in individuals with HCM.
EDG-7500 is an investigational therapy that has not been approved for use in hypertrophic cardiomyopathy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of this disease.
